An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition
- PMID: 12421831
- DOI: 10.1074/jbc.M208307200
An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition
Abstract
TEI-6720 (2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid) is an extremely potent inhibitor of xanthine oxidoreductase. Steady state kinetics measurements exhibit mixed type inhibition with K(i) and K(i)' values of 1.2 +/- 0.05 x 10(-10) m and 9 +/- 0.05 x 10(-10) m, respectively. Fluorescence-monitored titration experiments showed that TEI-6720 bound very tightly to both the active and the inactive desulfo-form of the enzyme. The dissociation constant determined for the desulfo-form was 2 +/- 0.03 x 10(-9) m; for the active form, the corresponding number was too low to allow accurate measurements. The crystal structure of the active sulfo-form of milk xanthine dehydrogenase complexed with TEI-6720 and determined at 2.8-A resolution revealed the inhibitor molecule bound in a long, narrow channel leading to the molybdenum-pterin active site of the enzyme. It filled up most of the channel and the immediate environment of the cofactor, very effectively inhibiting the activity of the enzyme through the prevention of substrate binding. Although the inhibitor did not directly coordinate to the molybdenum ion, numerous hydrogen bonds as well as hydrophobic interactions with the protein matrix were observed, most of which are also used in substrate recognition.
Similar articles
-
Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion.J Pharmacol Exp Ther. 2004 Nov;311(2):519-28. doi: 10.1124/jpet.104.070433. Epub 2004 Jun 9. J Pharmacol Exp Ther. 2004. PMID: 15190124
-
Mechanism of inhibition of xanthine oxidoreductase by allopurinol: crystal structure of reduced bovine milk xanthine oxidoreductase bound with oxipurinol.Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):888-93. doi: 10.1080/15257770802146577. Nucleosides Nucleotides Nucleic Acids. 2008. PMID: 18600558
-
Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.Life Sci. 2005 Mar 4;76(16):1835-47. doi: 10.1016/j.lfs.2004.10.031. Epub 2005 Jan 18. Life Sci. 2005. PMID: 15698861
-
[Inhibitors of xanthine oxidoreductase].Nihon Rinsho. 2008 Apr;66(4):748-53. Nihon Rinsho. 2008. PMID: 18409526 Review. Japanese.
-
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.Clin Ther. 2009 Nov;31(11):2503-18. doi: 10.1016/j.clinthera.2009.11.033. Clin Ther. 2009. PMID: 20109996 Review.
Cited by
-
Long-term inhibition of xanthine oxidase by febuxostat does not decrease blood pressure in deoxycorticosterone acetate (DOCA)-salt hypertensive rats.PLoS One. 2013;8(2):e56046. doi: 10.1371/journal.pone.0056046. Epub 2013 Feb 5. PLoS One. 2013. PMID: 23393607 Free PMC article.
-
Mutations associated with functional disorder of xanthine oxidoreductase and hereditary xanthinuria in humans.Int J Mol Sci. 2012 Nov 21;13(11):15475-95. doi: 10.3390/ijms131115475. Int J Mol Sci. 2012. PMID: 23203137 Free PMC article. Review.
-
Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.Cardiovasc Diabetol. 2016 Jun 18;15:87. doi: 10.1186/s12933-016-0409-2. Cardiovasc Diabetol. 2016. PMID: 27317093 Free PMC article. Clinical Trial.
-
Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics.Arthritis Res Ther. 2006;8 Suppl 1(Suppl 1):S4. doi: 10.1186/ar1909. Epub 2006 Apr 12. Arthritis Res Ther. 2006. PMID: 16820043 Free PMC article. Review.
-
Effectiveness of benzbromarone versus febuxostat in gouty patients: a retrospective study.Clin Rheumatol. 2022 Jul;41(7):2121-2128. doi: 10.1007/s10067-022-06110-5. Epub 2022 Feb 28. Clin Rheumatol. 2022. PMID: 35229198
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases